RVPH241220P7500
- 0.00
- 0.000.00%
Reviva Pharmaceuticals Newsroom
8-K: Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Reviva Pharmaceuticals Reports Q3 EPS (25c), Consensus (25c)
Reviva Pharmaceuticals Reports Progress on Brilaroxazine Trials and Financial Results for Q3 2024
Reviva Pharm Holdings 3Q Loss/Shr 25c >RVPH
Reviva Pharm Holdings Is Maintained at Buy by D. Boral Capital
Reviva Pharm Holdings Price Target Maintained With a $15.00/Share by D. Boral Capital
Press Release: Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Express News | Reviva Pharmaceuticals Q3 Net Income USD -8.4 Million
Express News | Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Express News | Reviva Pharmaceuticals Q3 EPS USD -0.25
10-Q: Q3 2024 Earnings Report
Express News | D. Boral Capital Maintains Buy on Reviva Pharmaceuticals, Maintains $15 Price Target
Maxim Group Keeps Their Hold Rating on Reviva Pharmaceuticals Holdings (RVPH)
Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia
Reviva to Present Positive Speech Latency Data for Brilaroxazine in Schizophrenia From the Phase 3 RECOVER Trial at the CNS Summit 2024
Reviva to Participate in the UBS Global Healthcare Conference
12 Health Care Stocks Moving In Thursday's After-Market Session
Reviva to Participate in the 2024 Maxim Healthcare Virtual Summit
Reviva Pharmaceuticals Schizophrenia Drug Demonstrates Strong Efficacy On Heels Of Bristol Myers, FDA Approval: Analyst
Reviva Pharm Holdings Price Target Announced at $15.00/Share by EF Hutton